Entscheidungsprozesse von Frauen mit erhöhtem Brustkrebsrisiko
Die Studie untersucht den Einfluss von sozialen, psychologischen und Umweltfaktoren auf die Entscheidungsfindung von Frauen für eine Chemoprävention.
Sie befinden sich hier:
The study "Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer (DMP-1)" is conducted by the NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP, www.nsabp.pitt.edu) and funded by the National Cancer Institute.
to describe the influence of social, environmental and psychological factors (sociality of medication intake, life-events, understanding of prevention, clinical situation) on the decision of women at risk for breast cancer for taking chemoprevention agents.
- understanding the implications of and influences on decision making that a diagnosis of 'being at risk for breast cancer' has for women,
- developing a survey that identified the factors that influence the decision-making process of women at high risk of breast cancer who are considering chemoprevention, and
- understanding what factors hinder women from taking chemoprevention for breast cancer.
Background and study details:
In the US tamoxifen and raloxifene, two selective estrogen receptor modulators (SERMs), are approved for breast cancer risk reduction since both SERMs have shown to reduce the risk of invasive breast cancer by 50%. However, previous research has shown that women have very little interest in taking a SERM to prevent a first diagnosis of breast cancer, despite their risk reducing capacities. The research that has investigated women's lack of interest in chemoprevention has primarily focused on women's perceptions of the risks and benefits of treatment. There may be other possible explanations for women's reluctance to begin chemoprevention. Factors, this study will explore. This research will use several approaches including surveys, in person interviews, and videotaping of clinical visits. We seek to recruit 100 women who choose to take a SERM. To do so, we will recruit up to 1000 women who discuss SERM use for breast cancer risk reduction. In addition, we videotape and analyze 30 consultation sessions with women at increased risk of developing breast cancer and their health care provider. Research participants will be recruited from a variety of clinics that serve the general US population (i.e., clinics from the Community Clinical Oncology Program and Minority Based Community Clinical Oncology Program*), and high-volume breast cancer risk clinics, such as MD Anderson Cancer Center in Texas and Fox Chase Cancer Center in Pennsylvania.
- Dr. phil. Christine Holmberg, M.P.H., M.A., IPH der Charité
- Angela Fagerlin, PhD, University of Michigan, Division of General Medicine
- Sarah Blakeslee, MScIH
- Jennifer Kennedy, MSc